BBOT
BridgeBio Oncology Therapeutics Inc.
Biotechnology
Market Cap$185M
5Y Perf.-26.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BBOT vs IQV
Revenue, margins, valuation, and 5-year total return — side by side.
IQV
IQVIA Holdings Inc.
Medical - Diagnostics & Research
Market Cap$30.32B
5Y Perf.-27.7%
BBOT vs IQV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BBOT | IQV |
|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $185M | $30.32B |
| Revenue (TTM) | $0.00 | $16.63B |
| Net Income (TTM) | $-134M | $1.39B |
| Gross Margin | — | 26.1% |
| Operating Margin | — | 13.9% |
| Forward P/E | — | 14.0x |
| Total Debt | $3M | $16.17B |
| Cash & Equiv. | $374M | $1.98B |
BBOT vs IQV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BBOT
IQV
| Stock | Feb 24 | May 26 | Return |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | 100 | 73.9 | -26.1% |
| IQVIA Holdings Inc. (IQV) | 100 | 72.3 | -27.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BBOT vs IQV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IQV leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. BridgeBio Oncology Therapeutics Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
BBOT
BridgeBio Oncology Therapeutics Inc.
The Income Pick
BBOT is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.96
- Lower volatility, beta 0.96, Low D/E 0.7%, current ratio 12.14x
- Beta 0.96, current ratio 12.14x
Best for: income & stability and sleep-well-at-night
IQV
IQVIA Holdings Inc.
The Growth Play
IQV carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 5.9%, EPS growth 4.7%, 3Y rev CAGR 4.2%
- 166.5% 10Y total return vs BBOT's -22.9%
- 5.9% revenue growth vs BBOT's -80.5%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IQV | 5.9% revenue growth vs BBOT's -80.5% |
| Stability / Safety | BBOT | Beta 0.96 vs IQV's 1.33, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IQV | +16.5% vs BBOT's -27.6% |
| Efficiency (ROA) | IQV | 4.7% ROA vs BBOT's -41.9%, ROIC 8.7% vs -96.3% |
BBOT vs IQV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
BBOT vs IQV — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIQVLAGGINGBBOT
BBOTBridgeBio Oncology Th…
1leads
IQVIQVIA Holdings Inc.
3leads
6 Total Categories
CATEGORYLEADERvs BBOTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IQV1/1
Valuation MetricsMultiples, price ratios, and targets
BBOT2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IQV4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
IQV5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IQV leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
IQV and BBOT operate at a comparable scale, with $16.6B and $0 in trailing revenue.
| Metric | BBOTBridgeBio Oncolog… | IQVIQVIA Holdings In… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $16.6B |
| EBITDAEarnings before interest/tax | -$166M | $3.5B |
| Net IncomeAfter-tax profit | -$134M | $1.4B |
| Free Cash FlowCash after capex | -$95M | $2.7B |
| Gross MarginGross profit ÷ Revenue | — | +26.1% |
| Operating MarginEBIT ÷ Revenue | — | +13.9% |
| Net MarginNet income ÷ Revenue | — | +8.3% |
| FCF MarginFCF ÷ Revenue | — | +16.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +8.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -21.2% | +15.0% |
IQV leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
BBOT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | BBOTBridgeBio Oncolog… | IQVIQVIA Holdings In… |
|---|---|---|
| Market CapShares × price | $185M | $30.3B |
| Enterprise ValueMkt cap + debt − cash | -$186M | $44.5B |
| Trailing P/EPrice ÷ TTM EPS | -1.83x | 22.79x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 13.96x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.56x |
| EV / EBITDAEnterprise value multiple | — | 12.97x |
| Price / SalesMarket cap ÷ Revenue | — | 1.86x |
| Price / BookPrice ÷ Book value/share | 0.60x | 4.67x |
| Price / FCFMarket cap ÷ FCF | — | 14.78x |
BBOT leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
IQV leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
IQV delivers a 22.1% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-66 for BBOT. BBOT carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to IQV's 2.44x.
| Metric | BBOTBridgeBio Oncolog… | IQVIQVIA Holdings In… |
|---|---|---|
| ROE (TTM)Return on equity | -65.5% | +22.1% |
| ROA (TTM)Return on assets | -41.9% | +4.7% |
| ROICReturn on invested capital | -96.3% | +8.7% |
| ROCEReturn on capital employed | -48.0% | +11.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 2.44x |
| Net DebtTotal debt minus cash | -$371M | $14.2B |
| Cash & Equiv.Liquid assets | $374M | $2.0B |
| Total DebtShort + long-term debt | $3M | $16.2B |
| Interest CoverageEBIT ÷ Interest expense | — | 3.10x |
IQV leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
IQV leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BBOT five years ago would be worth $7,713 today (with dividends reinvested), compared to $7,621 for IQV. Over the past 12 months, IQV leads with a +16.5% total return vs BBOT's -27.6%. The 3-year compound annual growth rate (CAGR) favors IQV at -2.0% vs BBOT's -8.3% — a key indicator of consistent wealth creation.
| Metric | BBOTBridgeBio Oncolog… | IQVIQVIA Holdings In… |
|---|---|---|
| YTD ReturnYear-to-date | -36.0% | -20.7% |
| 1-Year ReturnPast 12 months | -27.6% | +16.5% |
| 3-Year ReturnCumulative with dividends | -22.9% | -5.9% |
| 5-Year ReturnCumulative with dividends | -22.9% | -23.8% |
| 10-Year ReturnCumulative with dividends | -22.9% | +166.5% |
| CAGR (3Y)Annualised 3-year return | -8.3% | -2.0% |
IQV leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BBOT and IQV each lead in 1 of 2 comparable metrics.
Risk & Volatility
BBOT is the less volatile stock with a 0.96 beta — it tends to amplify market swings less than IQV's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IQV currently trades 72.3% from its 52-week high vs BBOT's 52.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BBOTBridgeBio Oncolog… | IQVIQVIA Holdings In… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.96x | 1.32x |
| 52-Week HighHighest price in past year | $14.87 | $247.05 |
| 52-Week LowLowest price in past year | $7.63 | $134.65 |
| % of 52W HighCurrent price vs 52-week peak | +52.9% | +72.3% |
| RSI (14)Momentum oscillator 0–100 | 41.2 | 58.5 |
| Avg Volume (50D)Average daily shares traded | 306K | 1.6M |
Evenly matched — BBOT and IQV each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BBOT as "Buy" and IQV as "Buy". Consensus price targets imply 175.7% upside for BBOT (target: $22) vs 25.3% for IQV (target: $224).
| Metric | BBOTBridgeBio Oncolog… | IQVIQVIA Holdings In… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $21.67 | $223.75 |
| # AnalystsCovering analysts | 3 | 44 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 2 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
IQV leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BBOT leads in 1 (Valuation Metrics). 1 tied.
Best OverallIQVIA Holdings Inc. (IQV)Leads 3 of 6 categories
Loading custom metrics...
BBOT vs IQV: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is BBOT or IQV a better buy right now?
IQVIA Holdings Inc.
(IQV) offers the better valuation at 22. 8x trailing P/E (14. 0x forward), making it the more compelling value choice. Analysts rate BridgeBio Oncology Therapeutics Inc. (BBOT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BBOT or IQV?
Over the past 5 years, BridgeBio Oncology Therapeutics Inc.
(BBOT) delivered a total return of -22. 9%, compared to -23. 8% for IQVIA Holdings Inc. (IQV). Over 10 years, the gap is even starker: IQV returned +166. 6% versus BBOT's -24. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BBOT or IQV?
By beta (market sensitivity over 5 years), BridgeBio Oncology Therapeutics Inc.
(BBOT) is the lower-risk stock at 0. 96β versus IQVIA Holdings Inc. 's 1. 32β — meaning IQV is approximately 38% more volatile than BBOT relative to the S&P 500. On balance sheet safety, BridgeBio Oncology Therapeutics Inc. (BBOT) carries a lower debt/equity ratio of 1% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — BBOT or IQV?
On earnings-per-share growth, the picture is similar: IQVIA Holdings Inc.
grew EPS 4. 7% year-over-year, compared to -1034. 8% for BridgeBio Oncology Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BBOT or IQV?
IQVIA Holdings Inc.
(IQV) is the more profitable company, earning 8. 3% net margin versus 0. 0% for BridgeBio Oncology Therapeutics Inc. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus 0. 0% for BBOT. At the gross margin level — before operating expenses — IQV leads at 26. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is BBOT or IQV more undervalued right now?
Analyst consensus price targets imply the most upside for BBOT: 175.
7% to $21. 67.
07Which pays a better dividend — BBOT or IQV?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is BBOT or IQV better for a retirement portfolio?
For long-horizon retirement investors, BridgeBio Oncology Therapeutics Inc.
(BBOT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 96)). Both have compounded well over 10 years (BBOT: -24. 8%, IQV: +166. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between BBOT and IQV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.